Qureight’s platform deployed in Rein Therapeutics’ IPF trial

Rein Therapeutics and Cambridge-based Qureight are collaborating on the development of LTI-03, a treatment for idiopathic pulmonary fibrosis (IPF), a devastating lung disease with a high mortality rate and limited treatment options.

LTI-03 is a first-in-class, dual-action peptide therapy that both halts the progression of fibrosis and supports the restoration of healthy lung tissue - thereby addressing two fundamental drivers of IPF in a way that current therapies don’t.

Dual mechanism drugs are one of the most important areas of pharmaceutical innovation in 2025, and the partnership boosts the sector’s claim to be seen to be tackling serious, hard-to-treat, health conditions for the benefit of patients.

Rein Therapeutics was incorporated in 2001 and is headquartered in Austin,Texas. As a clinical-stage biopharmaceutical company, it is advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications.

LTI-01 is Rein’s second product candidate and has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. It has received Orphan Drug Designation in the US and EU and Fast Track Designation in the US. a collaboration for the integration of Qureight’s deep-learning platform into Rein’s planned Phase 2 trial of its lead asset LTI-03, a novel, multi-pathway, Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis (IPF). The collaboration will integrate Qureight’s deep-learning platform into Rein’s planned Phase 2 trial of LTI-03.

Qureight’s cloud-based, vendor-agnostic Core Imaging Platform is GDPR, HIPPA and NHS Digital compliant. The platform has ISO13485 and ISO27001 accreditation to interrogate clinical trial data. The team is led by co-founder and CEO Dr Muhunthan Thillai, a pulmonologist who trained in lung fibrosis.

“In our Phase 1b clinical trial of LTI-03, we emphasized the importance of biomarkers for measuring progress in patients with IPF treated with LTI-03 as well as for illustrating the dual mechanism of LTI-03 in the body,” said Brian Windsor, president and CEO of Rein Therapeutics. “We are taking the evaluation of biomarkers a step further with the application of cutting-edge deep-learning imaging technology and detailed AI-based data analysis by collaborating with Qureight on this Phase 2 trial. These tools will be critical in gaining a deeper understanding of the potential therapeutic effect of LTI-03.”

Dr Thillai said: “We’re delighted that our core platform and AI technology will be supporting Rein Therapeutics in advancing its treatment, LTI-03, for patients with IPF. Our AI tools will provide precise, quantitative insights into how LTI-03 affects lung structure and function. This partnership represents another milestone in accelerating fibrotic lung disease treatment, which is so desperately needed for patients."

Rein plans to announce further details on the design of the Phase 2 trial of LTI-03 in IPF in the near term.